CClinicalTrials.gg
CompletedNCT06149416Updated Jun 6, 2025Results posted

SpO2 Accuracy of Noninvasive Pulse Oximeter Sensor With Motion Conditions

An interventional study of Experimental Masimo RD SET SpO2 Adhesive Sensors in Healthy and Hypoxia, sponsored by Stryker Sustainability Solutions. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Stryker Sustainability Solutions · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled May 2023, registered Nov 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this clinical study is to validate the SpO2 accuracy of the Stryker Sustainability Solutions pulse oximetry sensors during motion conditions over the range of 70 -100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry during conditions in which the subject is moving. The end goal is to provide supporting documentation for the SpO2 accuracy validation of the reprocessed sensors with motion indications.

Read the detailed description

In this study, the level of oxygen within the blood will be reduced in a controlled manner by reducing the concentration of oxygen the study volunteer breathes. The accuracy of a noninvasive pulse oximeter sensor will be assessed by comparison to the oxygen saturation measurements from a laboratory blood gas analyzer.

A machine will be used to induce motions of 20 mm during testing at a sine rate of 2Hz, 3Hz, and 4Hz. A third motion moves the arm a random distance of 0 to 30mm at a random speed up to 5Hz.

It is required that the Accuracy Root Mean Square (ARMS) performance of the Stryker pulse oximetry sensors will meet a specification of +/-3% with a target of +/-3% or better in motion conditions for the range of 70 - 100% SaO2 (typically, saturation is determined once with air breathing and then at three or six levels, e.g. 94%, 90%, 85%, 80%, 75% and 70% or 95%, 85% and 75% saturation for about 30-60 seconds or 60-90 seconds at each level), thereby demonstrating an acceptable SpO2 accuracy performance specification. This study should utilize a three level structure (95%, 85% and 75%).

02

Conditions studied

  • Healthy
  • Hypoxia

Browse trials for

03

In context

Hypoxia

1,231 studies on the registry are indexed under Hypoxia; 241 are open to participants now.

This study's enrollment of 11 is below the median of 45 across 853 interventional studies indexed under Hypoxia.

Browse Hypoxia studies →

Lead sponsor

Stryker Sustainability Solutions is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • The subject is male or female, aged ≥18 and \<50
  • The subject is in good general health with no evidence of any medical problems.
  • The subject is fluent in both written and spoken English
  • The subject has provided informed consent and is willing to comply with the study procedures

Exclusion criteria

Exclusion Criteria:

The subject is obese (BMI>30)

  • The subject has a known history of heart disease, lung disease, kidney or liver disease
  • Diagnosis of asthma, sleep apnea, or use of CPAP
  • Subject has diabetes
  • Subject has a clotting disorder
  • The subject a hemoglobinopathy or history of anemia, per subject report or the first blood sample, that in the opinion of the investigator, would make them unsuitable for study participation
  • The subject has any other serious systemic illness
  • The subject is a current smoker
  • Any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigators would interfere with the sensors working correctly
  • The subject has a history of fainting or vasovagal response
  • The subject has a history of sensitivity to local anesthesia
  • The subject has a diagnosis of Raynaud's disease
  • The subject has unacceptable collateral circulation based on exam by the investigator (Allen's test)
  • The subject is pregnant, lactating or trying to get pregnant
  • The subject is unable or unwilling to provide informed consent, or is unable or unwilling to comply with study procedures
  • The subject has any other condition, which in the opinion of the investigators would make them unsuitable for the study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Experimental Arms

    Experimental: Healthy adult participants All participants are enrolled in the test group and receive the noninvasive adhesive reprocessed pulse oximeter sensors

    Device: Experimental Masimo RD SET SpO2 Adhesive Sensors

Interventions

  • DeviceExperimental Masimo RD SET SpO2 Adhesive Sensors

    Masimo RD SET SpO2 Adhesive Sensors, Adult (4000 Adt), Adult \& Neonate (4003 Neo)

06

What researchers measure

Primary outcomes

  1. Accuracy of Sensor by Comparing SpO2 Percent Blood Oxygen Saturation to SaO2 Percent Blood Oxygen Saturation Utilizing Arms Calculation Calculation [Time Frame: 1 - 5 Hours]

    The outcome of this study is the accuracy of the SpO2 (percent oxygen saturation by pulse oximetry) measured by the Reprocessed Oximeter pulse oximetry sensors during motion conditions over the range of 70 - 100% saturation compared to SaO2 (percent oxygen saturation by co-oximetry from blood samples) from arterial blood samples. The accuracy is calculated using the Arms error between measured SpO2 and reference SaO2. The Arms must meet the 3% specification for each reprocessed pulse oximetry sensor style. Standard deviation of the differences is computed as the precision. Square root of the sum of the squares of bias and precision is computed as the Arms Error value.

    Time frame: 1 - 5 hours

07

Results

Posted Jun 6, 2025

Participant flow

Participant flow — Overall Study
MilestoneHealthy Adult Participants
Started11
Completed11
Not completed0

Outcome measures

PrimaryAccuracy of Sensor by Comparing SpO2 Percent Blood Oxygen Saturation to SaO2 Percent Blood Oxygen Saturation Utilizing Arms Calculation Calculation [Time Frame: 1 - 5 Hours]

The outcome of this study is the accuracy of the SpO2 (percent oxygen saturation by pulse oximetry) measured by the Reprocessed Oximeter pulse oximetry sensors during motion conditions over the range of 70 - 100% saturation compared to SaO2 (percent oxygen saturation by co-oximetry from blood samples) from arterial blood samples. The accuracy is calculated using the Arms error between measured SpO2 and reference SaO2. The Arms must meet the 3% specification for each reprocessed pulse oximetry sensor style. Standard deviation of the differences is computed as the precision. Square root of the sum of the squares of bias and precision is computed as the Arms Error value.

Time frame:
1 - 5 hours
Reported as:
Number · Root Mean Square Error (%)
Accuracy of Sensor by Comparing SpO2 Percent Blood Oxygen Saturation to SaO2 Percent Blood Oxygen Saturation Utilizing Arms Calculation Calculation [Time Frame: 1 - 5 Hours]
Root Mean Square Error (%)Masimo RD SET SpO2 Adhesive Sensors: Adult (4000 Adt), Adult & Neonate (4003)
Device 1 4000-Adt Accuracy1.84
Device 2 4003-Neo Accuracy2.33

Adverse events

Collected over 2 Days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Adult Participants0/11 (0%)0/11 (0%)0/11 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Healthy Adult Participants
<=18 years0
Between 18 and 65 years11
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Healthy Adult Participants
Female4
Male7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Healthy Adult Participants
Caucasian5
Black2
Asian2
Hispanic0
Multiethnic2
Region of Enrollment
Region of Enrollment(Participants)Healthy Adult Participants
United States11
08

Study locations

1 site
  • UCSF Hypoxia Research Laboratory
    San Francisco, California 94133, United States
09

References and documents

Study documents

  • Protocol, analysis plan and consent form · May 25, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06149416
Lead sponsor
Stryker Sustainability Solutions
Responsible party
Sponsor
First posted
Nov 29, 2023
Start date
May 27, 2023
Primary completion
May 28, 2023
Completion
May 28, 2023
Results posted
Jun 6, 2025
Last update
Jun 6, 2025

Study contacts

Philip Bickler, MD, PhD
principal investigator · UCSF Hypoxia Research Laboratory

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion